Pursuant to Regulation 30 of the SEBI Listing Regulations, we hereby wish to inform you that the Company has entered into a Securities Subscription Agreement and Shareholders' Agreement dated 23rd December, 2022 with Enzene Biosciences Limited, a subsidiary of the Company ('Enzene'), Eight Roads Ventures India Healthcare IV, L.P. ('Eight Roads Ventures') and F-Prime Capital Partners Life Sciences Fund VI LP ('F-Prime Capital') in connection with an acquisition of a minority stake by Eight Roads Ventures and F-Prime Capital in Enzene. In this regard, the necessary disclosures/ information required to be submitted pursuant to Regulation 30 of SEBI Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is enclosed as Annexure I. A copy of this disclosure will be made available on the Company's website as well in accordance with Regulation 30(8) of the SEBI Listing Regulations. Kindly take note of the same.